BofA raised the firm’s price target on Cellebrite (CLBT) to $25 from $24 and keeps a Buy rating on the shares. The firm fine tunes its estimates to reflect positive underlying trends following the company’s Q3 report.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite price target raised to $24 from $23 at JPMorgan
- Cellebrite DI: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- Cellebrite DI Positioned for Growth: Buy Rating Affirmed Amid Federal Demand Recovery and Strategic Alignments
- Cellebrite Reports Strong Q3 2025 Financial Results
- Closing Bell Movers: Cisco jumps 7% to record highs after beat-and-raise